Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond.  Our clinical stage products target specific cancers at the molecular level, and our companion diagnostics identify the patients with the corresponding molecular signature who are the best candidates for therapy.

Our products are based on our proprietary peptide targeted radionuclide technology which can image and subsequently kill cancer cells with directed radiotherapy. Three clinical trials with Tozaride (Re188-P2045) have been completed and Phase 2 studies are being planned.

Our team, with more than 75 years combined experience, Andarix is committed to creating treatments that produce significant and improved outcomes for cancer patients. Click here to learn more.

Christopher P. Adams is a visionary entrepreneur and innovator in the biotech and life sciences sector, currently serving as the Founder and CEO of Andarix, a clinical-stage company specializing in targeted radiolabeled therapeutics for cancer treatment. With a proven track record of founding and co-founding multiple life science and technology-based companies in Massachusetts, Mr. Adams has consistently demonstrated his ability to identify unmet medical needs and develop innovative solutions. His contributions span diverse areas, including obesity therapeutics, eye disease detection software, and genomics technology for colon cancer detection. Notably, he developed a cornea wound treatment technology that has become the current standard of care.

Throughout his career, Mr. Adams has made significant impacts in healthcare, with his technologies collectively being used on over 4 million patients worldwide. His innovative prowess is further evidenced by his portfolio of more than 20 issued U.S. and international patents covering medical devices, software, and pharmaceuticals. As a leader who combines scientific expertise with entrepreneurial acumen, Christopher P. Adams has consistently turned innovative ideas into marketable products, making him a compelling figure in the dynamic and high-potential biotech sector. His strategic thinking, market understanding, and commitment to advancing medical science position him as a key player in the industry, capable of driving growth and creating value for investors.